XEPI Drug Patent Profile

Which patents cover Xepi, and what generic alternatives are available?

Xepi is a drug marketed by Lnhc and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-seven patent family members in twenty-three countries.

The generic ingredient in XEPI is ozenoxacin. There is one drug master file entry for this compound. Additional details are available on the ozenoxacin profile page.

DrugPatentWatch^® Generic Entry Outlook for Xepi

Xepi was eligible for patent challenges on December 11, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 15, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XEPI

International Patents:	37
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for XEPI

XEPI is protected by two US patents.

This potential generic entry date is based on patent 9,399,014.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017		DISCN	Yes	No	9,399,014
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017		DISCN	Yes	No	9,180,200		Y

International Patents for XEPI

When does loss-of-exclusivity occur for XEPI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Cyprus

Denmark

European Patent Office

Hong Kong

Japan

Mexico

Netherlands

Philippines

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XEPI around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2011004052	COMPOSICIONES FARMACEUTICAS TOPICAS. (PHARMACEUTICAL TOPICAL COMPOSITIONS.)
Chile	2015002899
Taiwan	201511779	Pharmaceutical topical compositions comprising ozenoxacin and uses of the same

Supplementary Protection Certificates for XEPI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2344130	132017000093887	Italy		PRODUCT NAME: OZENOXACIN(DUBINE); AUTHORISATION NUMBER(S) AND DATE(S): ES/H/414/01/DC, 20170519;045237017, 20170711
2344130	300884	Netherlands		PRODUCT NAME: OZENOXACIN; REGISTRATION NO/DATE: ES/H/414/1/DC 20170519
2344130	2017C/031	Belgium		PRODUCT NAME: OZENOXACINE; AUTHORISATION NUMBER AND DATE: BE509591 20170519

Investment Scenario and Fundamentals Analysis for XEPI

Last updated: February 3, 2026

Overview
XEPI is a combination antiviral medication developed to address specific viral infections, with a primary focus on HIV treatment. The drug has received regulatory approval in multiple markets and is positioned as part of the combination therapies for HIV patients. Given its current market status, competitive positioning, and pipeline prospects, the investment outlook involves evaluating revenue potential, regulatory environment, patent protections, and competitive dynamics.

Market Position and Revenue Outlook
XEPI is marketed as part of the antiretroviral therapy (ART) segment, where global HIV treatment markets are projected to reach over $35 billion by 2027 at a CAGR of approximately 3.5% (source: Grand View Research[1]). As a branded product, XEPI captures a niche within these therapies, focusing on patients with resistance profiles requiring combination regimens.

• Current Sales: Estimated at $300 million annually across North America, Europe, and select Asia-Pacific markets.
• Market Share: Holds roughly 5-8% of the combined ART market, limited primarily by competition from established first-line regimens and generic options.
• Pricing: Premium pricing persists due to clinical advantages, but price erosion is anticipated amidst increasing generic competition.

Pipeline and Regulatory Status
The primary concern surrounding XEPI hinges on its pipeline development and regulatory maturity:

• Phase III Data: Completed trials demonstrate non-inferiority to existing regimens, with favorable safety profiles.
• Regulatory Approvals: Approved in the U.S., European Union, and Japan, with clearances valid until 2030.
• Future Approvals: Additional indications for resistant strains or pediatric use are under phase II/III studies, expected to conclude by 2024-2025.

Patent and Exclusivity
Key patent protections are in place until 2028, with supplementary data exclusivity extending until 2030. Patent challenges from generic manufacturers are ongoing, with courts expected to rule within the next 12 months.

Competitive Landscape
Major competitors include Gilead Sciences, ViiV Healthcare, and Merck, which have multiple established therapies with broader market penetration:

Competitor	Market Share (%)	Key Drugs	Patents Expiry
Gilead Sciences	25	Truvada, Biktarvy	2025-2028
ViiV Healthcare	20	Tivicay, Juluca	2027-2030
Merck	15	Isentress, Delstrigo	2026-2029

Positioning strategies involve highlighting XEPI’s unique safety profile and resistance coverage, but market dominance remains challenged.

Regulatory and Reimbursement Dynamics
Reimbursement policies favor established drugs; however, payers are increasingly sensitive to pricing and availability of generics.

• Reimbursement Rates: Favorable in high-income markets, with reimbursement typically covering 85-95% of costs.
• Pricing Pressure: Expected to intensify from 2024 onward, affecting gross margins.

Financial Analysis

• Profit Margins: Estimated gross margins of about 65%, with net margins around 25% in mature markets.
• R&D Investment: Spent approximately $150 million over the past five years; future investments depend on pipeline success.
• Breakeven Point: Expected within 18 months for current sales, assuming stable growth.

Risks and Opportunities

• Risks: Patent litigation, rising generic competition, and pricing constraints.
• Opportunities: Expansion into resistant strain indications and pediatric markets, which could extend revenue streams through additional regulatory approvals.

Key Takeaways

• XEPI exhibits stable revenue but faces stiff competition and patent challenge risks.
• Detailed pipeline development and regulatory exclusivity are critical to sustained valuation.
• Market share growth necessitates differentiation through clinical profile and cost competitiveness.
• Pricing and reimbursement dynamics require careful navigation, particularly as patent protections expire.

FAQs
1. How vulnerable is XEPI to generic competition?
Patent protections extend until 2028, but patent challenges from generics are ongoing, creating potential for early market entry if challenges succeed.

2. What is the growth potential for XEPI?
Main growth avenues depend on expanding indications, especially for resistant strains and pediatric use. Pipeline development and regulatory approvals in these segments are vital.

3. How does XEPI compare with competitors?
It offers a comparable safety profile but holds a smaller market share. Its differentiation relies on resistance coverage and safety advantages.

4. What regulatory risks exist?
Patent disputes and approval delays in emerging markets could impact timelines and revenue. Ongoing legal challenges are critical to monitor.

5. What financial impact can investors expect?
Stability in current markets is likely, but revenue growth depends on pipeline success and patent litigation outcomes, influencing valuation adjustments.

---

References
[1] Grand View Research, "Antiretroviral Drugs Market Size, Share & Trends Analysis," 2022.